Validation of an in-house developed therapeutic dosimetric software tool for the treatment of 177Lutetium-DOTATATE peptide receptor radionuclide therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Validation of an in-house developed therapeutic dosimetric software tool for the treatment of 177Lutetium-DOTATATE peptide receptor radionuclide therapy ; volume:14 ; number:2 ; day:13 ; month:2 ; year:2024 ; pages:277-289 ; date:3.2024
Health and Technology ; 14, Heft 2 (13.2.2024), 277-289, 3.2024
- Classification
-
Medizin, Gesundheit
- Creator
-
Wyk, Bronwin Van
Hasford, Francis
Nyakale, Nozipho
Vangu, Mboyo-Di-Tamba
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12553-024-00818-x
- URN
-
urn:nbn:de:101:1-2404291311003.597557245976
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wyk, Bronwin Van
- Hasford, Francis
- Nyakale, Nozipho
- Vangu, Mboyo-Di-Tamba
- SpringerLink (Online service)
Other Objects (12)
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review
Adsorption behavior of in-house developed CO2-philic anionic surfactants
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy
Publisher Correction: Adsorption behavior of in-house developed CO2-philic anionic surfactants
Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment
Inhouse Consulting
Inhouse-Systeme
177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
Radionuclide
Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review
Adsorption behavior of in-house developed CO2-philic anionic surfactants
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy
Publisher Correction: Adsorption behavior of in-house developed CO2-philic anionic surfactants
Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment
Inhouse Consulting
Inhouse-Systeme
177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
Radionuclide
Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review
Adsorption behavior of in-house developed CO2-philic anionic surfactants
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy
Publisher Correction: Adsorption behavior of in-house developed CO2-philic anionic surfactants
Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment
Inhouse Consulting
Inhouse-Systeme
177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
Radionuclide